This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. More recently, research activity has broadened to include the epidemiology and genetics of other communicable and of non-communicable diseases (NCDs), including cancer, cardiovascular disease and diabetes (2).
Supplementary Methods

Uganda
The General Population Cohort (GPC) was originally established in 1989, by the UK Medical Research Council (MRC) and the Uganda Virus Research Institute (UVRI), in Kalungu District, south-western Uganda, to examine prevalence, incidence, risk factors and trends of infection with the human immunodeficiency virus (HIV) in a rural African population (1) .
More recently, research activity has broadened to include the epidemiology and genetics of other communicable and of non-communicable diseases (NCDs), including cancer, cardiovascular disease and diabetes (2) .
In brief, the GPC is a community-based open cohort study of residents of neighbouring villages within one half of a sub-county, lying about 40km from the shores of Lake Victoria. The population is scattered across the countryside in villages defined by administrative boundaries with a few concentrated in small trading centres. Agriculture is the main economic activity with rain-fed, small-holder farms. A population of approximately 10,000 people in a cluster of 15 villages was studied from 1989 to 1999. In 2000 the GPC was expanded to cover a further For the purposes of this study, samples were collected from 302 volunteers aged 45 years and above who were selected to be seronegative for HIV-1 because HIV infection is known to increase the risk of developing lymphoma (3). They were recruited from study hypertension clinics and, where possible, from the wider cohort. Participants were asked to attend a special clinic at the central field station, where written informed consent was obtained, together with a sample of whole blood. Samples were transported in cool boxes to Entebbe where a full blood count was obtained on the same day; they were stored in a refrigerator at 4°C overnight and flow cytometry (FC) performed the following day, i.e. samples were less than 24 hours old on analysis. Those with blood counts or symptoms suggestive of B-cell disorders (fever, splenomegaly, lymphadenopathy) would have been excluded, but no individuals had these features. Local medical follow-up was provided for participants with haematology parameters outside of the normal range.
UK
The UK samples were obtained as reported previously (4) using anonymised waste material from hospital outpatients and primary care under approval of the research ethics committee.
Samples were selected according to the following criteria: normal leucocyte and differential counts, a normal platelet count and a normal haemoglobin level; the blood sample had to be less than 24 hours old and have come from a person visiting a general practice, ophthalmology, gynaecology, cardiology, dermatology, or orthopaedic pre-operative clinic, or the Accident and Emergency Department. Subjects were excluded if they had been visiting a haematology, oncology or transplant clinic, or had a sample sent for investigation of a cancer in the past.
Patients with immunological disorders were not specifically excluded. Samples were selected to match the age and sex distribution of the rural Ugandan participants. Although the UK cases are not from a general population, the prevalence of MBL is equivalent to other European general population studies(5,6) The UK cases represent a mixture of rural and urban populations as there is no reported difference in cancer incidence in the UK urban and rural populations (7) . All samples were obtained between 15 th January and 18 th December 2012. to define the positive/negative threshold which could be reproducibly performed across different instruments. Analysis with respect to CXCR5 analysis was not performed because this marker is heterogeneously expressed and while it is straightforward to discriminate abnormal expression patterns, the classification of positive and negative depends on instrument-specific settings and it was not possible to directly compare expression intensity between the different geographical locations. In order to ensure consistency of analysis, the same antibodies were used in the UK and Uganda, the operator in Uganda (AS) underwent specific training in the UK, and both datasets were independently reviewed by an additional operator (AR). Amplicons generated by first-round PCR were gel-purified and subsequently amplified with a unique MID-tagged, M13-containing 454 amplicon sequencing primer to enable multiplexing.
Flow cytometry
Immunoglobulin Heavy Chain Gene and Single Nucleotide Polymorphism (SNP) Analysis
Libraries were quantified with Quant-iT pico-green (Biorad), mixed, and sequenced using the standard Roche 454 GS-Junior sequencing protocol. Resultant data were filtered to remove low quality sequences; deconvoluted and primer/adapter sequences were trimmed. The filtered-in high-quality reads were analyzed using the IMGT HighV-Quest software (10) . Only productive, in-frame sequences were included in the analysis.
As part of the African Partnership for Chronic Disease Research, Genotype data have been generated at the Sanger Institute in Cambridge, UK, for 5000 participants of the GPC in Uganda, using the Illumina HumanOmni2.5 BeadChip array (2) . There are 30 common genetic variants reported to confer a modest increase in risk of developing CLL (11) and an association for 6 SNPs with the CLL-precursor lesion MBL has been confirmed (12) . Previously published risk allele frequency for the UK general population and for CLL patients was compared with the prevalence in participants of the GPC in Uganda
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